产品名称	Erenumab (anti-CALCRL), Antibody of CGRP receptor
英文别名	Calcitonin receptor-like receptor \| CGRP type 1 receptor
规格或纯度	ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
特异性	CALCRL
应用	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
种属反应性	Cynomolgus monkey,Human
偶联	Unconjugated
作用类型	拮抗剂
作用机制	Antibody of CGRP receptor

AI解读

产品属性

抗体类型	Primary antibody
克隆类型	Recombinant
Format	Whole IgG
亚型	Human IgG2SA
轻链亚型	lambda
SDS-PAGE	27.7 kDa (Light Chain) & 52.0 kDa (Heavy Chain), under reducing conditions; 175.2 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
来源	CHO supernatant
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	Lot by Lot
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息	1582205-90-0

图片

SEC: Erenumab (anti-CALCRL) (Ab170518)

Erenumab (anti-CALCRL) (Ab170518) - SEC
The purity of Erenumab (anti-CALCRL) (Ab170518) is more than 95% verified by HPLC.

关联靶点（人）

RAMP1 Tclin 受体活性修饰蛋白 1(Receptor activity-modifying protein 1) (0 活性数据)

点击查看靶蛋白信息： RAMP1

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

CALCRL Tclin 降钙素基因相关肽1型受体(Calcitonin gene-related peptide type 1 receptor) (0 活性数据)

点击查看靶蛋白信息： CALCRL

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

技术规格说明书

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到5个结果

批号(Lot Number)	证书类型	日期	货号
ZJ24F1214927	分析证书	24-12-06	Ab170518
ZJ24F1214926	分析证书	24-12-06	Ab170518
ZJ24F1214925	分析证书	24-12-06	Ab170518
ZJ24F0102480	分析证书	24-01-18	Ab170518
ZJ24F0102479	分析证书	24-01-18	Ab170518

此产品的引用文献

如何在您的发表作品中引用阿拉丁的产品和网站?

1. Hansen JM, Hauge AW, Olesen J, Ashina M. (2010) Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura.. Cephalalgia, 30 (10): (1179-86). [PMID:20855363] [10.1021/op500134e]
2. Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J et al.. (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.. Lancet Neurol, 15 (4): (382-90). [PMID:26879279] [10.1021/op500134e]
3. Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C. (2016) Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor.. J Pharmacol Exp Ther, 356 (1): (223-31). [PMID:26559125] [10.1021/op500134e]
4. Paemeleire K, MaassenVanDenBrink A. (2018) Calcitonin-gene-related peptide pathway mAbs and migraine prevention.. Curr Opin Neurol, 31 (3): (274-280). [PMID:29432219] [10.1021/op500134e]
5. Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA. (2018) ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.. Cephalalgia, 38 (6): (1026-1037). [PMID:29471679] [10.1021/op500134e]
6. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic.. Nat Rev Neurol, 14 (6): (338-350). [PMID:29691490] [10.1021/op500134e]
7. A-González N, Castrillo A. (2011) Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.. Biochim Biophys Acta, 1812 (8): (982-94). [PMID:21193033] [10.1021/op500134e]
8. Edvinsson L. (2018) The CGRP Pathway in Migraine as a Viable Target for Therapies.. Headache, 58 Suppl 1 (13): (33-47). [PMID:29697153] [10.1021/op500134e]
9. Mallee JJ, Salvatore CA, LeBourdelles B, Oliver KR, Longmore J, Koblan KS, Kane SA. (2002) Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists.. J Biol Chem, 277 (16): (14294-8). [PMID:11847213] [10.1021/op500134e]
10. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM. (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor.. Nature, 393 (6683): (333-9). [PMID:9620797] [10.1021/op500134e]
11. Aiyar N, Disa J, Pullen M, Nambi P. (2001) Receptor activity modifying proteins interaction with human and porcine calcitonin receptor-like receptor (CRLR) in HEK-293 cells.. Mol Cell Biochem, 224 (1-2): (123-33). [PMID:11693189] [10.1021/op500134e]
12. Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, Eberlein W. (2000) Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.. Br J Pharmacol, 129 (3): (420-3). [PMID:10711339] [10.1021/op500134e]
13. Salvatore CA, Hershey JC, Corcoran HA, Fay JF, Johnston VK, Moore EL, Mosser SD, Burgey CS, Paone DV, Shaw AW et al.. (2008) Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine.. J Pharmacol Exp Ther, 324 (2): (416-21). [PMID:18039958] [10.1021/op500134e]
14. Hay DL, Christopoulos G, Christopoulos A, Sexton PM. (2006) Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors--the role of receptor activity modifying protein 1.. Mol Pharmacol, 70 (13): (1984-1991). [PMID:16959943] [10.1021/op500134e]
15. Aiyar N, Rand K, Elshourbagy NA, Zeng Z, Adamou JE, Bergsma DJ, Li Y. (1996) A cDNA encoding the calcitonin gene-related peptide type 1 receptor.. J Biol Chem, 271 (19): (11325-9). [PMID:8626685] [10.1021/op500134e]
16. ter Haar E, Koth CM, Abdul-Manan N, Swenson L, Coll JT, Lippke JA, Lepre CA, Garcia-Guzman M, Moore JM. (2010) Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism.. Structure, 18 (9): (1083-93). [PMID:20826335] [10.1021/op500134e]
17. Hong Y, Hay DL, Quirion R, Poyner DR. (2012) The pharmacology of adrenomedullin 2/intermedin.. Br J Pharmacol, 166 (1): (110-20). [PMID:21658025] [10.1021/op500134e]
18. Liu H, Altenbach RJ, Carr TL, Chandran P, Hsieh GC, Lewis LG, Manelli AM, Milicic I, Marsh KC, Miller TR et al.. (2008) cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.. J Med Chem, 51 (22): (7094-8). [PMID:18983139] [10.1021/op500134e]
19. Kusano S, Kukimoto-Niino M, Hino N, Ohsawa N, Okuda K, Sakamoto K, Shirouzu M, Shindo T, Yokoyama S. (2012) Structural basis for extracellular interactions between calcitonin receptor-like receptor and receptor activity-modifying protein 2 for adrenomedullin-specific binding.. Protein Sci, 21 (2): (199-210). [PMID:22102369] [10.1021/op500134e]
20. Joshi P, Anderson C, Binch H, Hadida S, Yoo S, Bergeron D, Decker C, terHaar E, Moore J, Garcia-Guzman M et al.. (2014) Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists.. Bioorg Med Chem Lett, 24 (3): (845-9). [PMID:24405707] [10.1021/op500134e]
21. Hay DL, Garelja ML, Poyner DR, Walker CS. (2018) Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25.. Br J Pharmacol, 175 (1): (3-17). [PMID:29059473] [10.1021/op500134e]

参考文献

1. Hansen JM, Hauge AW, Olesen J, Ashina M. (2010) Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura.. Cephalalgia, 30 (10): (1179-86). [PMID:20855363] [10.1021/op500134e]
2. Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J et al.. (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.. Lancet Neurol, 15 (4): (382-90). [PMID:26879279] [10.1021/op500134e]
3. Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C. (2016) Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor.. J Pharmacol Exp Ther, 356 (1): (223-31). [PMID:26559125] [10.1021/op500134e]
4. Paemeleire K, MaassenVanDenBrink A. (2018) Calcitonin-gene-related peptide pathway mAbs and migraine prevention.. Curr Opin Neurol, 31 (3): (274-280). [PMID:29432219] [10.1021/op500134e]
5. Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA. (2018) ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.. Cephalalgia, 38 (6): (1026-1037). [PMID:29471679] [10.1021/op500134e]
6. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic.. Nat Rev Neurol, 14 (6): (338-350). [PMID:29691490] [10.1021/op500134e]
7. A-González N, Castrillo A. (2011) Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.. Biochim Biophys Acta, 1812 (8): (982-94). [PMID:21193033] [10.1021/op500134e]
8. Edvinsson L. (2018) The CGRP Pathway in Migraine as a Viable Target for Therapies.. Headache, 58 Suppl 1 (13): (33-47). [PMID:29697153] [10.1021/op500134e]
9. Mallee JJ, Salvatore CA, LeBourdelles B, Oliver KR, Longmore J, Koblan KS, Kane SA. (2002) Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists.. J Biol Chem, 277 (16): (14294-8). [PMID:11847213] [10.1021/op500134e]
10. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM. (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor.. Nature, 393 (6683): (333-9). [PMID:9620797] [10.1021/op500134e]
11. Aiyar N, Disa J, Pullen M, Nambi P. (2001) Receptor activity modifying proteins interaction with human and porcine calcitonin receptor-like receptor (CRLR) in HEK-293 cells.. Mol Cell Biochem, 224 (1-2): (123-33). [PMID:11693189] [10.1021/op500134e]
12. Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, Eberlein W. (2000) Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.. Br J Pharmacol, 129 (3): (420-3). [PMID:10711339] [10.1021/op500134e]
13. Salvatore CA, Hershey JC, Corcoran HA, Fay JF, Johnston VK, Moore EL, Mosser SD, Burgey CS, Paone DV, Shaw AW et al.. (2008) Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine.. J Pharmacol Exp Ther, 324 (2): (416-21). [PMID:18039958] [10.1021/op500134e]
14. Hay DL, Christopoulos G, Christopoulos A, Sexton PM. (2006) Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors--the role of receptor activity modifying protein 1.. Mol Pharmacol, 70 (13): (1984-1991). [PMID:16959943] [10.1021/op500134e]
15. Aiyar N, Rand K, Elshourbagy NA, Zeng Z, Adamou JE, Bergsma DJ, Li Y. (1996) A cDNA encoding the calcitonin gene-related peptide type 1 receptor.. J Biol Chem, 271 (19): (11325-9). [PMID:8626685] [10.1021/op500134e]
16. ter Haar E, Koth CM, Abdul-Manan N, Swenson L, Coll JT, Lippke JA, Lepre CA, Garcia-Guzman M, Moore JM. (2010) Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism.. Structure, 18 (9): (1083-93). [PMID:20826335] [10.1021/op500134e]
17. Hong Y, Hay DL, Quirion R, Poyner DR. (2012) The pharmacology of adrenomedullin 2/intermedin.. Br J Pharmacol, 166 (1): (110-20). [PMID:21658025] [10.1021/op500134e]
18. Liu H, Altenbach RJ, Carr TL, Chandran P, Hsieh GC, Lewis LG, Manelli AM, Milicic I, Marsh KC, Miller TR et al.. (2008) cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.. J Med Chem, 51 (22): (7094-8). [PMID:18983139] [10.1021/op500134e]
19. Kusano S, Kukimoto-Niino M, Hino N, Ohsawa N, Okuda K, Sakamoto K, Shirouzu M, Shindo T, Yokoyama S. (2012) Structural basis for extracellular interactions between calcitonin receptor-like receptor and receptor activity-modifying protein 2 for adrenomedullin-specific binding.. Protein Sci, 21 (2): (199-210). [PMID:22102369] [10.1021/op500134e]
20. Joshi P, Anderson C, Binch H, Hadida S, Yoo S, Bergeron D, Decker C, terHaar E, Moore J, Garcia-Guzman M et al.. (2014) Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists.. Bioorg Med Chem Lett, 24 (3): (845-9). [PMID:24405707] [10.1021/op500134e]
21. Hay DL, Garelja ML, Poyner DR, Walker CS. (2018) Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25.. Br J Pharmacol, 175 (1): (3-17). [PMID:29059473] [10.1021/op500134e]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Erenumab (anti-CALCRL), Antibody of CGRP receptor

库存信息

库存信息

库存信息

库存信息

基本信息

AI解读

产品属性

图片

关联靶点（人）

技术规格说明书

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关文档

此产品的引用文献

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器